These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 27424909)

  • 1. In Vivo Bioluminescent Imaging of ATP-Binding Cassette Transporter-Mediated Efflux at the Blood-Brain Barrier.
    Bakhsheshian J; Wei BR; Hall MD; Simpson RM; Gottesman MM
    Methods Mol Biol; 2016; 1461():227-39. PubMed ID: 27424909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioluminescent imaging of drug efflux at the blood-brain barrier mediated by the transporter ABCG2.
    Bakhsheshian J; Wei BR; Chang KE; Shukla S; Ambudkar SV; Simpson RM; Gottesman MM; Hall MD
    Proc Natl Acad Sci U S A; 2013 Dec; 110(51):20801-6. PubMed ID: 24297888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ATP-binding cassette transporters modulate both coelenterazine- and D-luciferin-based bioluminescence imaging.
    Huang R; Vider J; Serganova I; Blasberg RG
    Mol Imaging; 2011 Jun; 10(3):215-26. PubMed ID: 21496450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ABCG2/BCRP expression modulates D-Luciferin based bioluminescence imaging.
    Zhang Y; Bressler JP; Neal J; Lal B; Bhang HE; Laterra J; Pomper MG
    Cancer Res; 2007 Oct; 67(19):9389-97. PubMed ID: 17909048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioluminescent imaging of ABCG2 efflux activity at the blood-placenta barrier.
    Kumar JS; Wei BR; Madigan JP; Simpson RM; Hall MD; Gottesman MM
    Sci Rep; 2016 Feb; 6():20418. PubMed ID: 26853103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ABCG2- and ABCG4-mediated efflux of amyloid-β peptide 1-40 at the mouse blood-brain barrier.
    Do TM; Noel-Hudson MS; Ribes S; Besengez C; Smirnova M; Cisternino S; Buyse M; Calon F; Chimini G; Chacun H; Scherrmann JM; Farinotti R; Bourasset F
    J Alzheimers Dis; 2012; 30(1):155-66. PubMed ID: 22391220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier.
    Vlaming ML; Läppchen T; Jansen HT; Kivits S; van Driel A; van de Steeg E; van der Hoorn JW; Sio CF; Steinbach OC; DeGroot J
    Nucl Med Biol; 2015 Nov; 42(11):833-41. PubMed ID: 26264927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gemcitabine upregulates ABCG2/BCRP and modulates the intracellular pharmacokinetic profiles of bioluminescence in pancreatic cancer cells.
    Sun Y; Gu M; Zhu L; Liu J; Xiong Y; Wei Y; Li F
    Anticancer Drugs; 2016 Mar; 27(3):183-91. PubMed ID: 26556627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [(18)F]FDG is not transported by P-glycoprotein and breast cancer resistance protein at the rodent blood-brain barrier.
    Wanek T; Traxl A; Bankstahl JP; Bankstahl M; Sauberer M; Langer O; Kuntner C
    Nucl Med Biol; 2015 Jul; 42(7):585-9. PubMed ID: 25823393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier.
    Cisternino S; Mercier C; Bourasset F; Roux F; Scherrmann JM
    Cancer Res; 2004 May; 64(9):3296-301. PubMed ID: 15126373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of bioluminescence imaging dynamics by D-luciferin uptake and efflux mechanisms.
    Zhang Y; Pullambhatla M; Laterra J; Pomper MG
    Mol Imaging; 2012; 11(6):499-506. PubMed ID: 23084250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo and ex vivo regulation of breast cancer resistant protein (Bcrp) by peroxisome proliferator-activated receptor alpha (Pparα) at the blood-brain barrier.
    Hoque MT; Shah A; More V; Miller DS; Bendayan R
    J Neurochem; 2015 Dec; 135(6):1113-22. PubMed ID: 26465636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors Influencing Luciferase-Based Bioluminescent Imaging in Preclinical Models of Brain Tumor.
    Kim M; Gupta SK; Zhang W; Talele S; Mohammad AS; Laramy J; Mladek AC; Zhang S; Sarkaria JN; Elmquist WF
    Drug Metab Dispos; 2022 Mar; 50(3):277-286. PubMed ID: 34887255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein.
    Lee YJ; Kusuhara H; Jonker JW; Schinkel AH; Sugiyama Y
    J Pharmacol Exp Ther; 2005 Jan; 312(1):44-52. PubMed ID: 15448171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of inhibitors of ABCG2 by a bioluminescence imaging-based high-throughput assay.
    Zhang Y; Byun Y; Ren YR; Liu JO; Laterra J; Pomper MG
    Cancer Res; 2009 Jul; 69(14):5867-75. PubMed ID: 19567678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age-Dependent Regulation of the Blood-Brain Barrier Influx/Efflux Equilibrium of Amyloid-β Peptide in a Mouse Model of Alzheimer's Disease (3xTg-AD).
    Do TM; Dodacki A; Alata W; Calon F; Nicolic S; Scherrmann JM; Farinotti R; Bourasset F
    J Alzheimers Dis; 2016; 49(2):287-300. PubMed ID: 26484906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of P-gp and BCRP on pulmonary drug disposition assessed by PET imaging in rats.
    Mairinger S; Hernández-Lozano I; Filip T; Sauberer M; Löbsch M; Stanek J; Wanek T; Sake JA; Pekar T; Ehrhardt C; Langer O
    J Control Release; 2022 Sep; 349():109-117. PubMed ID: 35798092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ABCG2 is upregulated in Alzheimer's brain with cerebral amyloid angiopathy and may act as a gatekeeper at the blood-brain barrier for Abeta(1-40) peptides.
    Xiong H; Callaghan D; Jones A; Bai J; Rasquinha I; Smith C; Pei K; Walker D; Lue LF; Stanimirovic D; Zhang W
    J Neurosci; 2009 Apr; 29(17):5463-75. PubMed ID: 19403814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An electrically tight in vitro blood-brain barrier model displays net brain-to-blood efflux of substrates for the ABC transporters, P-gp, Bcrp and Mrp-1.
    Helms HC; Hersom M; Kuhlmann LB; Badolo L; Nielsen CU; Brodin B
    AAPS J; 2014 Sep; 16(5):1046-55. PubMed ID: 24934296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physical blood-brain barrier disruption induced by focused ultrasound does not overcome the transporter-mediated efflux of erlotinib.
    Goutal S; Gerstenmayer M; Auvity S; Caillé F; Mériaux S; Buvat I; Larrat B; Tournier N
    J Control Release; 2018 Dec; 292():210-220. PubMed ID: 30415015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.